Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.
Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G. Kröger NM, et al. Among authors: fauble v. Leukemia. 2015 Nov;29(11):2126-33. doi: 10.1038/leu.2015.233. Epub 2015 Aug 21. Leukemia. 2015. PMID: 26293647 Review.
Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.
Palmer J, Kosiorek HE, Wolschke C, Fauble VDS, Butterfield R 3rd, Geyer H, Scherber RM, Dueck AC, Gathany A, Mesa RA, Kroger N. Palmer J, et al. Among authors: fauble vds. Biol Blood Marrow Transplant. 2019 Nov;25(11):2267-2273. doi: 10.1016/j.bbmt.2019.07.001. Epub 2019 Jul 6. Biol Blood Marrow Transplant. 2019. PMID: 31288096 Free PMC article. Clinical Trial.
Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.
Jain T, Kunze KL, Mountjoy L, Partain DK, Kosiorek H, Khera N, Hogan WJ, Roy V, Slack JL, Noel P, Fauble VDS, Leis JF, Sproat L, Tefferi A, Patnaik MM, Mesa RA, Palmer J. Jain T, et al. Among authors: fauble vds. Blood Cancer J. 2020 Mar 10;10(3):36. doi: 10.1038/s41408-020-0302-9. Blood Cancer J. 2020. PMID: 32157091 Free PMC article.
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
Tamari R, Mughal TI, Rondelli D, Hasserjian R, Gupta V, Odenike O, Fauble V, Finazzi G, Pane F, Mascarenhas J, Prchal J, Giralt S, Hoffman R. Tamari R, et al. Among authors: fauble v. Bone Marrow Transplant. 2015 May;50(5):628-36. doi: 10.1038/bmt.2014.323. Epub 2015 Feb 9. Bone Marrow Transplant. 2015. PMID: 25665047 Free PMC article. Review.
Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.
Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR, Camoriano J, Noel P, Fauble V, Betcher J, Higgins MS, Gillette-Kent G, Tremblay LD, Peterson ME, Olsen JJ, Tibes R, Mesa RA. Cherington C, et al. Among authors: fauble v. Leuk Res. 2012 Sep;36(9):1147-51. doi: 10.1016/j.leukres.2012.04.021. Epub 2012 May 11. Leuk Res. 2012. PMID: 22578777
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, Mascarenhas J, Tamari R, Arcasoy MO, Davies J, Gergis U, Ukaegbu OC, Kamble RT, Storring JM, Majhail NS, Romee R, Verstovsek S, Pagliuca A, Vasu S, Ernst B, Atenafu EG, Hanif A, Champlin R, Hari P, Gupta V. Shanavas M, et al. Among authors: fauble v. Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40. doi: 10.1016/j.bbmt.2015.10.005. Epub 2015 Oct 19. Biol Blood Marrow Transplant. 2016. PMID: 26493563 Free PMC article. Clinical Trial.
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF, Sproat LZ, Fauble V, Mesa RA, Palmer J. Jain T, et al. Among authors: fauble v. Bone Marrow Transplant. 2019 Feb;54(2):204-211. doi: 10.1038/s41409-018-0226-1. Epub 2018 May 24. Bone Marrow Transplant. 2019. PMID: 29795431 Free PMC article.
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.
Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R. Bogenberger JM, et al. Among authors: fauble v. Leukemia. 2014 Aug;28(8):1657-65. doi: 10.1038/leu.2014.44. Epub 2014 Jan 23. Leukemia. 2014. PMID: 24451410 Free PMC article.
16 results